November 06, 2015 – Just about the same time at the End of October 2015, the American Drug and Food Administration (FDA) has approved, and the European Medicines Agency (EMA) has recommended for approval Talimogene Laherparepvec (Imlygic), a first-in-class advanced therapy medicinal product (ATMP) derived from a …

Imlygic, a first-of-its-kind oncolytic immunotherapy for the treatment of melanoma Read more »

April 30, 2014 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E mutation. Mekinist …

European Medicines Agency (EMA) recommends approval of Trametinib [Mekinist] for the treatment of melanoma with a BRAF V600E mutation Read more »

May 30, 2013 – From a Medscape News Release we learn today that two new drugs have been approved by the US Food and Drug Administration (FDA) for use in certain patients with metastatic or unresectable melanoma, along with a …

Dabrafenib [Tafinalar] and Trametinib [Mekinist] Approved for BRAF V600 Mutated Metastatic Melanoma Read more »